Description
Chair: Jean- Francois Chatal (ARRONAX), Rapporteur: Ulli Koester (ILL)
Otto Boerman,
W.J.G Oyen
(Radbout University Nijmegen Medical Centre)
03/02/2010, 08:30
Dr
F. HADDAD
(GIP ARRONAX and SUBATECH, Nantes)
03/02/2010, 09:00
Radioisotopes in diagnostics and therapy
Oral presentations
ARRONAX, acronym for "Accelerator for Research in Radiochemistry and Oncology at Nantes Atlantique", is a high energy and high intensity cyclotron. It will turn into operation in the beginning of 2010 in Nantes (France). It is mainly devoted to the production of radionuclides for medicine. A priority list based on the capability of the machine as well as on the need expressed by the European...
Dr
Matthias Miederer
(Universitätsmedizin Mainz, Germany)
03/02/2010, 09:10
Radioisotopes in diagnostics and therapy
Oral presentations
Radioimmunotherapy (RIT) of disseminated diseases in which individual cells or cell clusters are remaining requires a radionuclide that is capable of sterilizing individual cells with minimal radiotoxicity to surrounding healthy tissue. α particles exhibit high linear energy transfer and very short range in tissue, making them ideal for single-cell killing. 149Tb is a radiolanthanide that...
Dr
Richard Henkelmann
(Isotope Technologies Garching)
03/02/2010, 09:20
Radioisotopes in diagnostics and therapy
Oral presentations
177Lu is typically produced by direct irradiation with neutrons from enriched 176Lu. During direct irradiation of 176Lu remarkable amount of 177mLu (T1/2 = 160 d) is produced.
The 177mLu content in the labelling solution is mainly depending from the two factors: irradiation time and how much time has passed after end of the irradiation. Typically carrier added (c.a.) 177Lu is produced in...
Gerd Beyer
(Department of Radiology)
03/02/2010, 09:30
Radioisotopes in diagnostics and therapy
Oral presentations
Systemic radionuclide therapy is a very challenging field of nuclear medicine. The search of new tracers that may become a radiopharmaceutical is driven mainly by disciplines as biochemistry, organic chemistry and coordination chemistry, while modern radiochemical or nuclear physics achievements are often not adequately included. Frequently the development of new radiopharmaceuticals is...
N. Ramamoorthy
(IAEA Vienna)
03/02/2010, 10:30
03/02/2010, 10:55
Prof.
Dewi M. Lewis
(General Electric Healthcare)
03/02/2010, 10:55
Radioisotopes in diagnostics and therapy
Oral presentations
The Future for 99mTc and 99Mo in nuclear medicine
99mTc is an unusual radionuclide choice for imaging but has become the most frequently used radioisotope in nuclear medicine and has made single photon emission computed tomography (SPECT) an extremely powerful in-vivo diagnostic imaging tool. Recent advances in imaging camera technology offer a very promising future for this method of...
Mr
luca maciocco
(advanced accelerator applications)
03/02/2010, 11:15
Radioisotopes in diagnostics and therapy
Oral presentations
Feasibility study of an accelerator-driven production of Mo-99 for Tc-99m generators using a high-power LINAC
A compact accelerator-driven neutron activator based on a modified version of the Adiabatic Resonance Crossing (ARC) concept, proposed by C. Rubbia and experimentally demonstrated at CERN in 1997, has been developed with the aim of efficiently exploiting ion-beam generated neutrons...
Dr
Mark Harfensteller
(ITG Isotope Technologies Garching, Germany)
03/02/2010, 11:35
Radioisotopes in diagnostics and therapy
Oral presentations
The 68Ge/68Ga radionuclide generator (68Ge, T1/2 = 270.95 d) is an excellent cyclotron-independent source for the positron emitter 68Ga which is successfully used in clinical PET. Nevertheless there remain open problems in the routine use related to the applicability of the technique in clinical environment and legal aspects.
An effective application of the generator produced 68Ga can be...
